Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke

Ischemic stroke represents a leading cause of morbidity and mortality in the developed world. This disabling and sometimes fatal event puts an ever increasing burden on the family members and medical professionals who care for stroke victims. Preclinical ischemic stroke research has predominantly ut...

Full description

Saved in:
Bibliographic Details
Published in:The Yale journal of biology & medicine 2012-12, Vol.85 (4), p.523-539
Main Authors: Lucke-Wold, Brandon P, Turner, Ryan C, Lucke-Wold, A Noelle, Rosen, Charles L, Huber, Jason D
Format: Article
Language:English
Subjects:
Age
Age Factors
Aging
Animal models
Animals
Brain Ischemia - etiology
Brain research
Comorbidity
Cytokines
Diabetes
Diabetes mellitus
Disease
Disease Models, Animal
Focus: Neuroscience
Humans
Hypertension
Immune system
Inflammation
Ischemia
Medical personnel
Metabolic syndrome
Metabolic Syndrome - complications
Morbidity
Mortality
Nervous system
Nitric oxide
Pathophysiology
Risk Factors
Senescence
Stroke
Stroke - etiology
Translation
Young adults
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ischemic stroke represents a leading cause of morbidity and mortality in the developed world. This disabling and sometimes fatal event puts an ever increasing burden on the family members and medical professionals who care for stroke victims. Preclinical ischemic stroke research has predominantly utilized young adult, healthy animals, a clear discrepancy when considering the clinical population affected by stroke. A broad spectrum of risk factors such as age, obesity, diabetes, and hypertension has been associated with an increased stroke risk. The effect of these comorbidities on both stroke pathophysiology and outcome has not been emphasized and has been recognized as a shortcoming of preclinical studies. By addressing these conditions in experimental models of ischemic stroke, it may be possible to more accurately represent the clinical scenario and improve therapeutic translation from bench-to-bedside. In this work, we review many of the risk factors associated with increased stroke risk, particularly as each risk factor relates to inflammation. Additionally, we explore potential animal models that could be utilized in identifying the contribution of these risk factors to stroke outcome. By investigating the risk factors for stroke and how these may alter stroke pathophysiology, the present discrepancies between preclinical studies and the clinical reality can be reconciled in an effort to improve therapeutic development and translation from bench-to-bedside.
ISSN:0044-0086
1551-4056